6/5/2025 - 9:39 AM EST - Knight Therapeutics Inc. : And Sumitomo Pharma America Inc. announced today that Knight and SMPA’s affiliates have entered into exclusive license and supply agreements to commercialize MYFEMBREE® (relugolix/estradiol/norethindrone acetate), ORGOVYX® (relugolix) and vibegron in Canada, as well as an asset purchase agreement under which Knight will acquire certain mature products (the “Mature Products”, together with MYFEMBREE®, ORGOVYX® and vibegron, the “Products”). For the year ended March 2025, the Products generated $11.2 million in revenue. Knight Therapeutics Inc.
shares T.GUD are trading unchanged at $5.82.
